XOMA Corp (XOMA) reported quarterly earnings results on Wednesday, Aug-3-2016. The company reported $-0.13 EPS for the quarter. Analysts had a consensus estimate of $-0.13. The company posted revenue of $.40 million in the period, compared to analysts expectations of $.84 million. During the same quarter in the previous year, the company posted $-0.20 EPS.
XOMA Corp closed down -0.01 points or -1.56% at $0.63 with 6,96,744 shares getting traded on Tusday. Post opening the session at $0.63, the shares hit an intraday low of $0.62 and an intraday high of $0.6701 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Mar 22, 2016, Thomas M. Burns (VP, Finance & Chief Financial) sold 19,249 shares at $0.79 per share price. According to the SEC, on Mar 22, 2016, James R Neal (VP Business Development) sold 19,813 shares at $0.79 per share price. On Mar 22, 2016, Paul D Rubin (Sr. VP Clinical Dev. & CMO) sold 24,194 shares at $0.79 per share price, according to the Form-4 filing with the securities and exchange commission.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead product candidate gevokizumab is a potent humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate posterior or pan-uveitis (NIU) and Behcet’s disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program which includes EYEGUARD-A (patients with active NIU) EYEGUARD-B (patients with Behcet’s disease uveitis outside of the United States) and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).